Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13871545 | 0.78 | CNR1 (0.43) | ALDH1A1SMN1; SMN2EPHX2MEN1KMT2A | |
| SCHEMBL25890643 | 0.71 | EPHX2 (0.47) | HTR2CSLC6A4HTR2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13889388 | 0.69 | MEN1 (0.43) | MEN1KMT2A | |
| SCHEMBL13871668 | 0.69 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2A | |
| SCHEMBL14027598 | 0.68 | ALDH1A1 (0.40) | HTR2AALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13889389 | 0.68 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10216634 | 0.68 | PRCP (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL3467155 | 0.68 | MEN1 (0.42) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13889471 | 0.66 | CNR1 (0.43) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13871552 | 0.66 | CNR1 (0.43) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | LAGU BHARAT | 2009-04-16 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | CNR2, CNR1, GPR18 | HTR2C 9/4885SLC6A4 551/4885HTR2A 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.